The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Thyroid Cancers MORE >>

Lenvatinib demonstrated promising antitumor activity and a manageable toxicity profile in 3 main subtypes of thyroid cancer, according to findings recently published in Future Oncology.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.